Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …

Olaparib (Lynparza®), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has
recently been approved in a new tablet formulation as maintenance treatment for recurrent …

Introduction: Olaparib (Lynparza®) is an oral, small molecule, poly (ADP-ribose) polymerase
inhibitor that has become the first 'personalized'therapy available for patients with BRCA …

Olaparib (Lynparza™) is a first-in-class, orally-active, small molecule, poly (ADP-ribose)
polymerase inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. In …

Olaparib is the first oral poly (ADP‐ribose) polymerase inhibitor to be approved as
maintenance monotherapy for treatment of patients with platinum‐sensitive relapsed BRCA …

Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …

Objective: SOLO2 (ENGOT Ov-21; NCT01874353) evaluated the efficacy and tolerability of
the tablet formulation of olaparib (Lynparza), an oral PARP inhibitor (PARPi), in patients with …

Olaparib is a poly (ADP-ribose) polymerase inhibitor that received accelerated approval
from the US Food and Drug Administration as monotherapy for patients with germline BRCA …

Background Olaparib (AZD2281) is an oral poly (adenosine diphosphate [ADP]–ribose)
polymerase inhibitor that has shown antitumor activity in patients with high-grade serous …

5527 Background: To establish the maximum-tolerated dose (MTD) and evaluate dose-
limiting toxicities (DLTs) and response to therapy of combination therapy with …